Why Is Cytokinetics Inc. (NASDAQ: CYTK) The Best Stock of the Day?

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Founded in 1997, Cytokinetics Inc. focuses on muscle biology, developing muscle activators and inhibitors that improve overall function. These medications most often serve patients with cardiovascular or neuromuscular disorders. After an IPO in 2004, the company has continued to grow with licensing and funding deals the world over. 

Cytokinetics Inc. CYTK Change

As Cytokinetics grows, it is riding positive news. The stock is up over $8 at press time, totaling more than a 45% change. Over the past year, the stock has risen, experienced a selloff, and grown from that selloff only to drop once again. The most recent positive news involving the company signifies yet another major jump in its value.

Why is CYTK Moving?

Cytokinetics, as reported by Benzinga News, is reporting positive results from the first two cohorts of its CK-274 medication for hypertrophic cardiomyopathy (HCM). With Phase 3 trials set to begin before the end of 2021, the firm should remain in the news and continually see increases in its stock price.

Where to Buy Cytokinetics Inc. Stock

Use this list of brokers curated by Benzinga. Choose the broker that you are most comfortable with, complete a trade today and buy into CYTK stock before its price jumps once again.
 

Broker

Best For

Overall Rating

Start Trading

Webull

Intermediate Traders

4.5 Stars

Get Started

Interactive Brokers

Lowest Fees

5 Stars

Get Started

Robinhood

Beginner Traders

4 Stars

Get Started

Moomoo

Active Traders

5 Stars

Get Started

TD Ameritrade

Day Traders

5 Stars

Get Started

 

Stay Ahead of the Game on CYTK

Staying ahead of the game on CYTK stock is just as important as investing. You want to know how stocks are performing, review current events and make wise choices to increase your net worth.

Data for Cytokinetics Inc. as of July 19, 2021

Summary of Cytokinetics Inc. as of July 19, 2021:

  • Price Change: $19.230 to $27.914
  • 52 Week Low: $14.71
  • 52 Week High: $30.14
  • Market Cap: $1.386B
  • P/E Ratio: -
  • Dividend Yield: -

Significant Dates for Cytokinetics Inc.:

  • Next Earnings Date: August 5th, 2021
  • Last Earnings Date: May 6th, 2021, EPS of $-0.660
  • Ex-Dividend Date: -
  • Dividend Payment Date: -

Technical Data of Cytokinetics Inc. as of July 19, 2021:

  • RSI: 74.7 ⮕ Bullish
  • MACD: Signal Line (-0.6378) Over MACD (0.6392) ⮕ Bearish
  • Bollinger Bands: Price ($27.914) 20-Day SMA ($20.2628), Lower Band ($16.6871), Upper Band ($25.1229) ⮕ Neutral

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
 

Posted In: Small CapMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.